CN1408365A - Local applied medicine composition for curing subcutaneous tumor - Google Patents
Local applied medicine composition for curing subcutaneous tumor Download PDFInfo
- Publication number
- CN1408365A CN1408365A CN 01141824 CN01141824A CN1408365A CN 1408365 A CN1408365 A CN 1408365A CN 01141824 CN01141824 CN 01141824 CN 01141824 A CN01141824 A CN 01141824A CN 1408365 A CN1408365 A CN 1408365A
- Authority
- CN
- China
- Prior art keywords
- treatment
- pharmaceutical composition
- cancer
- arsenic trioxide
- subcutaneous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The locally applied medicine composition for treating subcutaneous tumor includes As2O3 in effective amount and pharmaceutically acceptable carrier. It is used in treating primary skin cancer, melanin cancer or metastatic subcutaneous cancer.
Description
Technical field
The present invention relates to a kind of local application pharmaceutical composition for the treatment of Subcutaneous tumor, particularly can be used for treating the local application pharmaceutical composition of primary cutaneous cancer, malignant melanoma or the subcutaneous cancer of transitivity.
Background technology
Arsenic trioxide can be used as herbicide and uses, and also can be used for killing rodent and insecticide.Can be used as parasiticide on the general medicine, also be a kind of composition that is present in Chinese medicine, the purposes in its main medical treatment is to treat anemia and dyspepsia, also can be used as the pulp devitalizer of treatment disease of pulp of tooth; It also treats psoriasis, syphilis and rheumatism with the principle of " treating the poisonous disease with poisonous drugs ".When the 1820's, arsenic trioxide has been considered to a kind of potential carcinogen, especially skin carcinoma and pulmonary carcinoma altogether of human malignancies.Because it has carcinogenecity, how medical application now only is used for the treatment of the african trypanosomiasis relevant with the central nervous system.
Yet discovering in recent years, arsenic trioxide is a kind of extremely effectively leukemia agent, can treat acute promyelocytic leukemia effectively, and this has seen in many documents.For example, Blood, the 88th volume, the 3rd phase, 1996, the 1052-1061 pages or leaves; European Journal ofCancer, the 35th volume, the 8th phase, 1999, the 1258-1263 pages or leaves and The New England Journalof Medicine, the 339th volume, the 19th phase, 1998, the 1341-1348 pages or leaves.
Above-mentioned document is not narrated the effect of arsenic trioxide treatment tumor, especially the treatment disease relevant with Subcutaneous tumor.
Summary of the invention
The present inventor is surprised to find that the local application arsenic trioxide can be used for treating the relevant disease of Subcutaneous tumor.
Purpose of the present invention is for providing a kind of local application pharmaceutical composition that is used for the treatment of Subcutaneous tumor.
Another object of the present invention provides a kind of local application pharmaceutical composition for the treatment of the primary cutaneous cancer, and it comprises the arsenic trioxide and the pharmaceutically acceptable carrier for the treatment of effective dose.
Another purpose of the present invention provides a kind of local application pharmaceutical composition for the treatment of malignant melanoma.
Another purpose more of the present invention provides a kind of local application pharmaceutical composition for the treatment of the subcutaneous cancer of transitivity.
Description of drawings
Below with reference to accompanying drawing the present invention is described in more detail, in the accompanying drawings:
Fig. 1 is according to the present invention, through the size of coating and the mice back tumor of the uncoated arsenic trioxide Ointment in Treatment figure to growth time.
Fig. 2 is the photo of the preceding mice back tumor of coating arsenic trioxide Ointment in Treatment.
Fig. 3 is the photo of mice back tumor after the coating arsenic trioxide Ointment in Treatment.
The specific embodiment
(chemical formula is As to arsenic trioxide among the present invention
2O
3), not soluble in water for white or transparent armorphous block of material or crystallization, have sweet taste.It has intensive toxicity, generally is used for making materials such as glass, enamel more.
Pharmaceutical composition of the present invention has excellent curative effect, for example primary cutaneous cancer, malignant melanoma (melanomatous cancer) or the subcutaneous cancer of transitivity cancers such as (metastaticcutaneous cancer) to the relevant disease of Subcutaneous tumor.Wherein the primary cutaneous cancer comprises basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and Merkel cell cancer.
" the treatment effective dose " mentioned herein for when using the mammal that needs this treatment, is enough to provide the consumption of therapeutic efficiency.The treatment effective dose will be decided with different factors such as the seriousness of the individuality of treatment and disease, this individual body weight and age, disease, medicament administration modes, and this can be determined by those skilled in the art.Be applicable to the arsenic trioxide concentration of the treatment effective dose of pharmaceutical composition of the present invention, be preferably 0.01 to 1 milligram/gram, more preferably 0.1 to 0.5 milligram/gram.
Pharmaceutical composition of the present invention is the medicine of local application, and it can manufacture local application dosage form well known in the art, for example ointment, spray, ointment, lotion, gel, paste, pomade or Emulsion etc. and similar dosage form thereof.Pharmaceutical composition of the present invention also can be coated on plaster or the bandage material and use.The mode that pharmaceutical composition of the present invention is used is covered in Subcutaneous tumor place for this pharmaceutical composition directly being coated on the plaster that Subcutaneous tumor maybe will contain this pharmaceutical composition, is preferably to apply once every day.
" pharmaceutically acceptable carrier " herein refers to any inert carrier that is applicable to the local application medicine well known in the art, for example, and organic solvent, antiseptic, emulsifying agent, suspending agent, diluent, gel or extender.
Pharmaceutical composition of the present invention can any method known to those skilled in the art be prepared into the dosage form of above-mentioned local application.In the embodiment preferred for example of the present invention, stearic acid, spermol, anhydrous lanolin, vegetable oil, triethanolamine (TEA), arsenic trioxide and water that uniform mixing is an amount of are made the pharmaceutical composition of emulsion-type.
The following example further specifies exploitativeness of the present invention, and it is used so that the technology of the present invention content is more concrete, but not in order to limit the scope of the invention.Other those skilled in the art are based on the spirit of known technology and achievable many variations of the present invention and improvement all should belong to category of the present invention.Embodiment 1 arsenic trioxide ointment composition of the present invention
The therapeutic efficiency of embodiment 2 pharmaceutical compositions of the present invention
| Composition | Content | Form (%) |
| Arsenic trioxide | 0.33 milligram | ????0.033 |
| Stearic acid | 9.6 milligram | ????0.96 |
| Spermol | 7.2 milligram | ????0.72 |
| | 80 milligrams | ????8.0 |
| Vegetable oil | 12.8 milligram | ????1.28 |
| Triethanolamine (TEA) | 16 milligrams | ????1.6 |
| Water | 873.65 milligram | ????87.4 |
| Amount to | 1 gram | ????100 |
HTB-9 cell strain (bladder cancer cell line is derived from American type culture collection, and preserving number is ATCC HTB-9) is cultivated at 37 ℃, in the Constant Temperature Incubators of 5% carbon dioxide with RPMI (10%FCS).After being cultured to sufficient amount, cell is separated on culture plate, clean and be diluted to debita spissitudo (2 * 10 with PBS again with trypsin
6Cell/50 microlitres).Cell strain after the dilution is implanted near the back forelimb of big female BALB/c-Hfhllnu mice (available from national Experimental Animal Center) in 18 eight ages in week subcutaneous or hind leg is subcutaneous, record tumor growth situation.
When tumor growth after about 19 days, promptly size reaches and is about 240 millimeters
3The time, the mice of being tried is divided into three groups (6 every group) begins to use pharmaceutical composition of the present invention.The arsenic trioxide ointment of first group of coating embodiment 1 composition is in the mouse tumor position; Second group is matched group, does not use any medicine; The 3rd group then is coated with arsenic trioxide ointment that embodiment 1 forms partly has the mice of wound in tumor tumor locus.The mode of using ointment each one, is about 0.14 gram for applying weekly three times (Monday, Wednesday and Friday).Observe the health status of these three groups of mices, the body weight of survival natural law and weighing mice.The tumor size utilizes the digital metric chi to measure length, width and height, and the account form of its volume is gross tumor volume (millimeter 3)=long (millimeter) * wide (millimeter) * height (millimeter).After 80 days the observation,, after coating arsenic trioxide Ointment in Treatment, all can suppress growth of tumor significantly by a definite date no matter whether tumor locus has wound.
With the result of medicine composite for curing mice of the present invention and the growth situation of mice in control group back tumor size, as shown in Figure 1.Again as shown in Figures 2 and 3, during uncoated arsenic trioxide ointment, tumor site presents tangible cerise; After accepting the treatment of coating arsenic trioxide ointment, tumor site gradually is black, and this demonstrates arsenic trioxide ointment and suppresses the obvious effect that Subcutaneous tumor had.
Claims (8)
1. local application pharmaceutical composition that is used for the treatment of Subcutaneous tumor, it comprises the arsenic trioxide and the pharmaceutically acceptable carrier for the treatment of effective dose.
2. pharmaceutical composition as claimed in claim 1, it can be used for treating the subcutaneous cancer of primary cutaneous cancer, malignant melanoma or transitivity.
3. local application pharmaceutical composition for the treatment of the primary cutaneous cancer, it comprises the arsenic trioxide and the pharmaceutically acceptable carrier for the treatment of effective dose.
4. local application pharmaceutical composition for the treatment of malignant melanoma, it comprises the arsenic trioxide and the pharmaceutically acceptable carrier for the treatment of effective dose.
5. local application pharmaceutical composition for the treatment of the subcutaneous cancer of transitivity, it comprises the arsenic trioxide and the pharmaceutically acceptable carrier for the treatment of effective dose.
6. as claim 1,3,4 or 5 described pharmaceutical compositions, wherein the concentration of arsenic trioxide is 0.1 to 0.5 milligram/gram.
7. pharmaceutical composition as claimed in claim 3, wherein the primary cutaneous cancer comprises basal cell carcinoma, squamous cell carcinoma or Merkel cell cancer.
8. as claim 1,3,4 or 5 described pharmaceutical compositions, it further comprises the medicine of other treatment Subcutaneous tumor.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01141824 CN1256096C (en) | 2001-09-19 | 2001-09-19 | Local applied medicine composition for curing subcutaneous tumor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01141824 CN1256096C (en) | 2001-09-19 | 2001-09-19 | Local applied medicine composition for curing subcutaneous tumor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1408365A true CN1408365A (en) | 2003-04-09 |
| CN1256096C CN1256096C (en) | 2006-05-17 |
Family
ID=4676431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01141824 Expired - Fee Related CN1256096C (en) | 2001-09-19 | 2001-09-19 | Local applied medicine composition for curing subcutaneous tumor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1256096C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010133087A1 (en) * | 2009-05-18 | 2010-11-25 | The University Of Hong Kong | Compositions and methods for treating inflammatory arthritis |
-
2001
- 2001-09-19 CN CN 01141824 patent/CN1256096C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010133087A1 (en) * | 2009-05-18 | 2010-11-25 | The University Of Hong Kong | Compositions and methods for treating inflammatory arthritis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1256096C (en) | 2006-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4826830A (en) | Topical application of glyciphosphoramide | |
| Niedner et al. | Inhibition of wound healing by antiseptics | |
| DE69909794T2 (en) | USE OF A DIPEPTID FOR RECOVERY PROCESSES | |
| DE60118889T2 (en) | FARNESYL PROTEIN TRANSFERASE INHIBITORS FOR THE TREATMENT OF BREAST CANCER | |
| DE19831579B4 (en) | Anticancer drug from arsenic hexoxide | |
| DE4100975A1 (en) | Cosmetic or pharmaceutical preparations for improving hair quality and promoting hair growth | |
| DE3784695T2 (en) | Use of Gramineae extracts as a medicine. | |
| DE69819514T2 (en) | USE OF PHYSIOLOGICALLY COMPATIBLE VANADIUM COMPOUNDS, SALTS AND COMPLEXES | |
| Mai et al. | Synergistic effect of bismuth subgallate and borneol, the major components of Sulbogin®, on the healing of skin wound | |
| CN115634282A (en) | Application of mussel mucin product in treating and preventing melanin-related diseases | |
| UA76415C2 (en) | Use of biguanide derivatives for making medicine having wound healing effect | |
| CA2251617A1 (en) | Medicament and method of treating an organism with medicaments | |
| CN1256096C (en) | Local applied medicine composition for curing subcutaneous tumor | |
| DE1917283C3 (en) | Manufacture of antimicrobial preparations | |
| DE4300969C2 (en) | Use of Malotilat to accelerate wound healing in case of skin burns | |
| CN103432049A (en) | Composition with deodorization function | |
| US20050196464A1 (en) | Method and pharmaceutical composition for treatment of skin neoplasm | |
| KR101948233B1 (en) | Compositions for Preventing Hair Loss and Stimulating Hair Sprouting | |
| TWI257866B (en) | Pharmaceutical composition for topical administration for the treatment of subcutaneous tumors | |
| DE102007046799A1 (en) | Skin care composition and method | |
| WO2000050085A2 (en) | Oil-in-water emulsion for the use as medicament or for producing a medicament | |
| CN107149568A (en) | A kind of preparation method of Itch Stopping Gel | |
| DE69935889T2 (en) | Polyphosphoric acid-containing cell growth accelerator and its use | |
| CN115364097B (en) | Application of pyridone derivative containing heteroatom cyclobutane substituent | |
| WO2021109704A1 (en) | Chronic wound healing composition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060517 Termination date: 20180919 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |